Literature DB >> 22551723

Evidence that deletion at FCGR3B is a risk factor for systemic sclerosis.

C McKinney1, J C A Broen, M C Vonk, L Beretta, R Hesselstrand, N Hunzelmann, G Riemekasten, R Scorza, C P Simeon, V Fonollosa, P E Carreira, N Ortego-Centeno, M A Gonzalez-Gay, P Airo, M Coenen, J Martin, T R D J Radstake, T R Merriman.   

Abstract

There is increasing evidence that gene copy number (CN) variation influences clinical phenotype. The low-affinity Fc receptor 3B (FCGR3B) located in the FCGR gene cluster is a CN polymorphic gene involved in the recruitment of polymorphonuclear neutrophils to sites of inflammation and their activation. Given the genetic overlap between systemic lupus erythematosus and systemic sclerosis (SSc) and the strong evidence for FCGR3B CN in the pathology of SLE, we hypothesised that FCGR3B gene dosage influences susceptibility to SSc. We obtained FCGR3B deletion status in 777 European Caucasian cases and 1000 controls. There was an inverse relationship between FCGR3B CN and disease susceptibility. CN of ≤ 1 was a significant risk factor for SSc (OR=1.55 (1.13-2.14), P=0.007) relative to CN ≥ 2. Although requiring replication, these results suggest that impaired immune complex clearance arising from FCGR3B deficiency contributes to the pathology of SSc, and FCGR3B CN variation is a common risk factor for systemic autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22551723     DOI: 10.1038/gene.2012.15

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  19 in total

1.  HNA-1, -3, -4, and -5 genotyping using multiplex PCR among southern Thais: Developing continual HNA-1 null detection.

Authors:  Kamphon Intharanut; Wiradee Sasikarn; Supattra Mitundee; Oytip Nathalang
Journal:  J Clin Lab Anal       Date:  2018-08-13       Impact factor: 2.352

Review 2.  The genetics of scleroderma: looking into the postgenomic era.

Authors:  Maureen D Mayes
Journal:  Curr Opin Rheumatol       Date:  2012-11       Impact factor: 5.006

3.  The Immunogenetics of Systemic Sclerosis.

Authors:  Begüm Ünlü; Ümit Türsen; Zeynab Rajabi; Navid Jabalameli; Fateme Rajabi
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  Elevated activating Fc gamma receptors levels correlated with susceptibility and severity of IgA nephropathy.

Authors:  Hongfen Li; Youxia Liu; Huyan Yu; Fanghao Wang; Junya Jia; Tiekun Yan; Shan Lin
Journal:  Ther Adv Chronic Dis       Date:  2022-06-27       Impact factor: 4.970

Review 5.  Association between FCGR3B copy number variations and susceptibility to autoimmune diseases: a meta-analysis.

Authors:  Young Ho Lee; Sang-Cheol Bae; Young Ho Seo; Jae-Hoon Kim; Sung Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  Inflamm Res       Date:  2015-09-25       Impact factor: 4.575

6.  Low copy number of FCGR3B is associated with lupus nephritis in a Chinese population.

Authors:  Zhaohui Zheng; Ruohan Yu; Congcong Gao; Xianan Jian; Songxia Quan; Guolan Xing; Shengyun Liu; Zhangsuo Liu
Journal:  Exp Ther Med       Date:  2017-08-30       Impact factor: 2.447

7.  FCGR3A and FCGR3B copy number variations are risk factors for sarcoidosis.

Authors:  Jianming Wu; Yunfang Li; Weihua Guan; Kevin Viken; David M Perlman; Maneesh Bhargava
Journal:  Hum Genet       Date:  2016-04-08       Impact factor: 5.881

8.  No Association between FC γ R3B Copy Number Variation and Susceptibility to Biopsy-Proven Giant Cell Arteritis.

Authors:  Emma Dunstan; Sue Lester; Rachel Black; Maureen Rischmueller; Helen Chan; Alex W Hewitt; Catherine L Hill
Journal:  Arthritis       Date:  2013-08-20

Review 9.  Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?

Authors:  Sietse Q Nagelkerke; Taco W Kuijpers
Journal:  Front Immunol       Date:  2015-01-21       Impact factor: 7.561

10.  CNVrd, a read-depth algorithm for assigning copy-number at the FCGR locus: population-specific tagging of copy number variation at FCGR3B.

Authors:  Hoang tan Nguyen; Tony R Merriman; Michael A Black
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.